Targeted Agent Rova-T Active in Small-Cell Lung Cancer

Video

This video discusses the phase I trial of rovalpituzumab (Rova-T) for the treatment of patients with small-cell lung cancer.

Currently, topotecan is the only US Food and Drug Administration (FDA)-approved agent for the treatment of relapsed small-cell lung cancer (SCLC).

In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses a phase I trial of rovalpituzumab (Rova-T), a novel agent that targets DLL3 that has shown activity in the second-line treatment of patients with SCLC.

Kalemkerian gave a presentation on SCLC at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

Tim Cortese
February 5th 2025
Article

The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

The mean number of palliative care visits was nearly halved for stepped-palliative care vs early palliative care in patients with advanced lung cancer.

Stepped Care Model for Lung Cancer May Maintain QOL With Fewer Visits

Roman Fabbricatore
August 6th 2024
Article

The mean number of palliative care visits was nearly halved for stepped-palliative care vs early palliative care in patients with advanced lung cancer.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies

Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies

Richard Lazzaro, MD
June 13th 2024
Article

"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."

Phase 3 data also show an improvement in deterioration-free survival with TTFields and best supportive care in those with NSCLC and brain metastases.

TTFields Combo Prolongs Time to Progression in NSCLC Brain Metastasis Group

Jordyn Sava
June 6th 2024
Article

Phase 3 data also show an improvement in deterioration-free survival with TTFields and best supportive care in those with NSCLC and brain metastases.